

Sonia Morè, MD

CURRICULUM VITAE AND STUDIORUM

Nata il 18/02/1991 a Macerata (MC), Italia.

Contatti: Medico in Formazione Specialistica presso SOD Clinica di Ematologia, AOU Ospedali Riuniti Umberto I- G.M. Lancisi- G.Salesi – Università Politecnica delle Marche. Via Conca 71, 60126 Torrette di Ancona, Italia.

Telefono 071 5964735 Fax 0715964230

e-mail: sonia.more@live.it

Titoli di studio

- Laurea in Medicina e Chirurgia presso Università Politecnica delle Marche, ottenuta in data 26/07/2016 (voto: 110/110 e lode)
- Abilitazione all'attività di Medico Chirurgo ottenuta in data 15/02/2017, (iscrizione all'Ordine dei Medici Chirurghi e Odontoiatrici di Macerata, N. 2577)
- Laurea Specialistica in Ematologia, conseguita in data 14/01/2022 (voto: 50/50 e lode).

Attività professionali

- Frequentatrice presso SOD di Ematologia, AOU Ospedali Riuniti Ancona da settembre 2015 a dicembre 2017;
- Medico in Formazione Specialistica presso la Clinica di Ematologia Azienda Ospedali Riuniti Ancona Università Politecnica delle Marche di Ancona da dicembre 2017

Pubblicazioni/Attività di ricerca

- Dynamic Features Occurring during Multiple Myeloma Course Can Modify the Outcome Predicted at Diagnosis By R-ISS Stage. *Massimo Offidani, Laura Corvatta, Sonia Morè, Valerio Mori, Silvia Gentili, Kimberly Blaine Garvey, Alessandra Bossi, Laura Maracci, Pietro Leoni. Blood (2016) 128 (22): 3263.*
- Dinamic predictive factors for a better stratification of patients with R-ISS II newly diagnosed multiple myeloma. *M. Offidani, L. Corvatta, L. Maracci, K. Garvey, S. Gentili, S. Morè, V. Mori, P. Leoni. Haematologica 2017, PB1954.*
- High proportion of patients with multiple myeloma received many different lines after frontline therapy: a single italian tertiary centre experience. *S. Morè, L. Corvatta, V. Mori, L. Maracci, G. Mancini, I. Scortechini, S. Gentili, A. Olivieri, M. Offidani. P036, Haematologica 2019*
- Clinical features and outcomes of newly diagnosed 1q+ multiple myeloma patients receiving new-drug containing regimens. *M. Offidani, S. Morè, L. Corvatta, V. Mori, L. Maracci, S. Trappolini, S. Gentili, G. Discepoli, A. Olivieri. P030, Haematologica 2019*
- Subcutaneous bortezomib-containing regimens as up-front treatment of newly diagnosed transplant-eligible multiple myeloma patients: a retrospective, non interventional observational study GLAL-2020-1294. *Rizzello, Ilaria; Cavo, Michele; Dozza, Luca; Rivolti, Elena; Petrucci, Maria Teresa; De Stefano, Valerio; Antonioli, Elisabetta; Tosi, Patrizia; D'Agostino, Mattia; Morè, Sonia; Gozzetti, Alessandro; Cea, Michele; Barbato, Simona; Tacchetti, Paola; Pantani, Lucia; Mancuso, Katia; Rocchi, Serena; De Cicco, Gabriella; Fusco, Alessio; Zamagni, Elena. Leuk&Lymphoma 2020*
- Developments in consolidation and maintenance strategies in post-remission multiple myeloma. *Sonia Morè, Laura Corvatta, Laura Maracci, Benedetta Costantini, Attilio Olivieri, Massimo Offidani. Exp Rev of Haematology, 2020, pag 351-362*

- Monoclonal Antibodies: Leading Actors in the Relapsed/Refractory Multiple Myeloma Treatment. *Sonia Morè, Maria Teresa Petrucci, Laura Corvatta, Francesca Fazio, Massimo Offidani and Attilio Olivieri. Pharmaceuticals 2020, 13, 426*
- Novel Experimental Drugs for Treatment of Multiple Myeloma. *Massimo Offidani, Laura Corvatta, Sonia Morè, Attilio Olivieri. Journal of Experimental Pharmacology 2021;13 245–264.*
- SINGLE VS DOUBLE TRANSPLANTATION OUTCOMES IN NEWLY DIAGNOSED MULTIPLE MYELOMA: A REAL LIFE ANALYSIS. *Sonia Morè, Laura Corvatta, Laura Maracci, Giorgia Mancini, Ilaria Scortechini, Attilio Olivieri, Massimo Offidani. HemaSphere 2021; 5 (S1) P17.*
- Daratumumab for the Management of Newly Diagnosed and Relapsed/Refractory Multiple Myeloma: Current and Emerging Treatments. *Massimo Offidani, Laura Corvatta, Sonia Morè, Davide Nappi, Giovanni Martinelli, Attilio Olivieri and Claudio Cerchione. Front. Oncol., 17 February 2021 <https://doi.org/10.3389/fonc.2020.624661>*
- Belantamab Mafodotin for the Treatment of Multiple Myeloma: An Overview of the Clinical Efficacy and Safety. *Massimo Offidani, Laura Corvatta, Sonia Morè, Attilio Olivieri. Drug Design, Development and Therapy, 2021*
- A single centre retrospective analysis on the ability to identify transplant-ineligible patients with multiple myeloma (MM) who are not likely to benefit from new standard therapies. *Massimo Offidani, Sonia Morè, Laura Corvatta, Valentina Maria Manieri, Attilio Olivieri. P168. 18th International Myeloma Workshop 2021*
- Identifying transplant-ineligible patients (NTE) with Multiple Myeloma (MM) who may not benefit from new standard therapies: a retrospective analysis of a single centre. *S. Morè, L. Corvatta, V.M. Manieri, A. Olivieri, M. Offidani. P52. Haematologica 2021*
- Response to BNT162b2 Sars-Cov-2 Vaccine in Recipients of Allogeneic Hematopoietic Stem Cell Transplant. *Francesco Saraceni, Alessandro Fiorentini, Sonia Morè et al. Blood 2021*
- Upstaging ISS and R-ISS by Platelet Count: Real-Life Analysis of 321 MM Patients. *M. Offidani, L. Corvatta, S. Morè et al. CLML 2019*
- Factors associated with the probability to skip subsequent lines of therapy: analysis of 321 multiple myeloma (MM) patients in a single tertiary centre. *M. Offidani, S. Morè, L. Corvatta et al. CLML 2019.*

Ancona, 20/01/2022

Sonia Morè

